RU2018137032A3 - - Google Patents

Download PDF

Info

Publication number
RU2018137032A3
RU2018137032A3 RU2018137032A RU2018137032A RU2018137032A3 RU 2018137032 A3 RU2018137032 A3 RU 2018137032A3 RU 2018137032 A RU2018137032 A RU 2018137032A RU 2018137032 A RU2018137032 A RU 2018137032A RU 2018137032 A3 RU2018137032 A3 RU 2018137032A3
Authority
RU
Russia
Application number
RU2018137032A
Other languages
Russian (ru)
Other versions
RU2760733C2 (ru
RU2018137032A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018137032A publication Critical patent/RU2018137032A/ru
Publication of RU2018137032A3 publication Critical patent/RU2018137032A3/ru
Application granted granted Critical
Publication of RU2760733C2 publication Critical patent/RU2760733C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2018137032A 2016-03-25 2017-03-20 Пиримидины и их варианты, и их применение RU2760733C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (3)

Publication Number Publication Date
RU2018137032A RU2018137032A (ru) 2020-04-27
RU2018137032A3 true RU2018137032A3 (cg-RX-API-DMAC7.html) 2020-05-22
RU2760733C2 RU2760733C2 (ru) 2021-11-30

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018137032A RU2760733C2 (ru) 2016-03-25 2017-03-20 Пиримидины и их варианты, и их применение

Country Status (11)

Country Link
US (2) US10662162B2 (cg-RX-API-DMAC7.html)
EP (1) EP3433258B1 (cg-RX-API-DMAC7.html)
JP (1) JP6902045B2 (cg-RX-API-DMAC7.html)
KR (1) KR102377805B1 (cg-RX-API-DMAC7.html)
CN (1) CN108779119B (cg-RX-API-DMAC7.html)
AU (1) AU2017237929B2 (cg-RX-API-DMAC7.html)
CA (1) CA3018180C (cg-RX-API-DMAC7.html)
MA (1) MA44489A (cg-RX-API-DMAC7.html)
MX (1) MX384368B (cg-RX-API-DMAC7.html)
RU (1) RU2760733C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017165255A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
KR102377805B1 (ko) 2016-03-25 2022-03-22 애퍼런트 파마슈티컬스 인크. 피리미딘 및 그의 변이체, 및 그의 용도
AU2017381739B2 (en) 2016-12-19 2020-06-11 Novartis Ag New picolinic acid derivatives and their use as intermediates
US10676444B2 (en) * 2016-12-20 2020-06-09 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
US11414444B2 (en) 2017-11-01 2022-08-16 Beijing Tide Pharmaceutical Co., Ltd. P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
KR20220008286A (ko) * 2019-04-30 2022-01-20 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법
WO2020221275A1 (zh) * 2019-04-30 2020-11-05 北京泰德制药股份有限公司 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途
US20220211703A1 (en) * 2019-04-30 2022-07-07 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
EP3981765A4 (en) * 2019-06-06 2023-05-31 Beijing Tide Pharmaceutical Co., Ltd. P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE
CN120058573B (zh) * 2025-04-29 2025-12-23 潍坊学院 一种1-三溴甲基磺酰基萘及其衍生物的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
EP1345926B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2005229331B2 (en) * 2004-03-05 2011-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as P2X3 and P2X2/3 antagonists
WO2007025899A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1924566B1 (en) * 2005-09-01 2016-01-13 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
BRPI0615040A2 (pt) * 2005-09-01 2011-04-26 Hoffmann La Roche diaminopirimidinas como moduladores de p2x3 e p2x2/3
EP1924565B1 (en) * 2005-09-01 2016-09-14 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
EP2079713B1 (en) * 2006-10-04 2014-04-16 F. Hoffmann-La Roche AG Process for synthesis of phenoxy diaminopyrimidine derivatives
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
AU2008319735A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as P2X7 receptor inhibitors
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
NZ716977A (en) * 2013-08-23 2017-09-29 Afferent Pharmaceuticals Inc Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases
EP3981406A1 (en) * 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
KR102377805B1 (ko) * 2016-03-25 2022-03-22 애퍼런트 파마슈티컬스 인크. 피리미딘 및 그의 변이체, 및 그의 용도

Also Published As

Publication number Publication date
RU2760733C2 (ru) 2021-11-30
MA44489A (fr) 2019-01-30
CN108779119B (zh) 2022-02-08
US20200239421A1 (en) 2020-07-30
MX2018011622A (es) 2019-03-28
US10662162B2 (en) 2020-05-26
US20190055202A1 (en) 2019-02-21
MX384368B (es) 2025-03-14
CA3018180C (en) 2024-02-20
EP3433258B1 (en) 2023-07-19
AU2017237929B2 (en) 2021-04-15
JP6902045B2 (ja) 2021-07-14
AU2017237929A1 (en) 2018-09-13
KR102377805B1 (ko) 2022-03-22
JP2019510025A (ja) 2019-04-11
EP3433258A4 (en) 2019-10-30
EP3433258A1 (en) 2019-01-30
WO2017165255A1 (en) 2017-09-28
RU2018137032A (ru) 2020-04-27
CA3018180A1 (en) 2017-09-28
KR20180128015A (ko) 2018-11-30
BR112018069105A2 (pt) 2019-01-29
US11230532B2 (en) 2022-01-25
CN108779119A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
BR112019009262A2 (cg-RX-API-DMAC7.html)
BR112019000402A2 (cg-RX-API-DMAC7.html)
BR112018071172A2 (cg-RX-API-DMAC7.html)
BR112019009373A2 (cg-RX-API-DMAC7.html)
BR112019003108A2 (cg-RX-API-DMAC7.html)
CN303672280S (cg-RX-API-DMAC7.html)
CN303613232S (cg-RX-API-DMAC7.html)
CN303536126S (cg-RX-API-DMAC7.html)
CN303536221S (cg-RX-API-DMAC7.html)
CN303536237S (cg-RX-API-DMAC7.html)
CN303536241S (cg-RX-API-DMAC7.html)
CN303536262S (cg-RX-API-DMAC7.html)
CN303536272S (cg-RX-API-DMAC7.html)
CN303536511S (cg-RX-API-DMAC7.html)
CN303536541S (cg-RX-API-DMAC7.html)
CN303536542S (cg-RX-API-DMAC7.html)
CN303536616S (cg-RX-API-DMAC7.html)
CN303537182S (cg-RX-API-DMAC7.html)
CN303537318S (cg-RX-API-DMAC7.html)
CN303537475S (cg-RX-API-DMAC7.html)
CN303537476S (cg-RX-API-DMAC7.html)
CN303537528S (cg-RX-API-DMAC7.html)
CN303537545S (cg-RX-API-DMAC7.html)
CN303537688S (cg-RX-API-DMAC7.html)
CN303537759S (cg-RX-API-DMAC7.html)